Selling before or after rescheduling

Where rescheduling stands in September 2026

Half done. The order published 28 April 2026 placed two things in Schedule III: FDA-approved drug products containing marijuana, and marijuana subject to a state medical marijuana licence. Gibson Dunn’s summary confirms that all other marijuana, which includes the adult-use market, remains in Schedule I.

The broader question went to an expedited DEA hearing. According to a 29 July 2026 status summary:

• The hearing ran from 29 June to 15 July 2026.
• Post-hearing briefs were due 17 August 2026.
• The administrative law judge’s recommendation is expected in late 2026.
• Parties then have 20 days to file objections, and the record goes to the DEA Administrator, who is not bound by the recommendation.
• A final decision can be challenged in the D.C. Circuit.

So there is no date. A final adult-use rule could arrive in 2027, later, or not at all, and could be stayed by a court after it arrives. The full history is on the rescheduling status page.

What rescheduling changes for a seller, and what it does not

Changes	Does not change
280E stops applying to activity no longer in Schedule I or II. Treasury said on 23 April 2026 this will run from the full tax year that includes the effective date, with apportionment for mixed businesses.	State licensing, ownership-change approval, and local control. Your sale process is the same.
After-tax cash flow, and so what buyers can pay.	SBA ineligibility and bank caution. The SAFE Banking Act of 2026 is introduced, not enacted.
Access to U.S. exchanges for medical-only companies, per Akerman.	Interstate commerce. Each state market stays closed.
Investor sentiment and the number of buyers looking.	Oversupply and price compression in your state.

The arithmetic of 280E relief

Illustrative only. An adult-use dispensary has $4.0 million revenue, $2.0 million cost of goods, and $1.4 million operating expenses, so pre-tax profit is $0.6 million.

	Under 280E	Without 280E
Federal taxable income	$2.0 million (gross profit)	$0.6 million
Federal tax at 21%	$420,000	$126,000
After-tax cash flow	$180,000	$474,000

After-tax cash flow rises by $294,000 a year. If the market capitalised all of that at 4x, the business would be worth about $1.2 million more. In practice it will not all reach you. Buyers already weight the probability in current offers, competition bids some of the saving away over time, and new capital raises supply of competing stores as well as demand for yours. Model your own figures with the rescheduling impact calculator; the valuation logic is in how rescheduling would affect valuation and the tax cases in rescheduling tax scenarios.

Scenario planning for owners

Scenario	What it means for an adult-use seller
Final rule moves all marijuana to Schedule III in 2027 and survives challenge	280E ends for adult-use. Valuations and buyer numbers rise. Sellers who waited benefit, if their state market held up.
Final rule issued but stayed or tied up in court	Extended uncertainty. Buyers keep discounting. Waiting costs time with no uplift.
Administrator declines to reschedule adult-use	Status quo. Medical and adult-use are valued on different tax bases indefinitely.
Congress acts first, on banking or broader reform	Could help more than rescheduling, for example on lending. Timing equally unknown.

You cannot know which row you are in. You can decide how much of your net worth should depend on it.

Decision table: sell now or wait?

Your situation	Leaning
Medical-only or medical-heavy licence	The tax uplift has already happened. Waiting for the adult-use decision adds little. Sell on post-April-2026 earnings.
Adult-use, profitable after 280E, in a limited-licence state, no pressure to exit	Waiting is affordable. Reassess when the judge’s recommendation is published.
Adult-use in an oversupplied state with falling prices	Market decline may outrun any tax uplift. See selling in an oversupplied market. Leaning sell.
Behind on taxes, debt maturing, or partners in dispute	Time is not on your side. A sale now, from a position you still control, usually beats a forced sale later.
Owner at or near retirement, health concerns, or burnout	Personal timing outweighs a policy bet. Leaning sell, with upside protection.
Dual medical and adult-use	Separate the books and show both cases. Either timing can work.

Selling now without giving away the upside

You do not have to choose between a sale today and the rescheduling uplift. Deal terms can split it.

1. Rescheduling earn-out. An extra payment if adult-use marijuana leaves Schedule I, or if the business’s federal tax falls for that reason, within a set period such as 24 or 36 months. Define the trigger precisely: publication of a final rule, its effective date, or the first tax year the buyer files without 280E.
2. Retained equity. Keep a minority stake so you share in any rerating. It must be disclosed to the regulator, and you remain tied to the buyer’s performance.
3. Seller note with a kicker. A note whose principal or rate steps up on the trigger.
4. Refund sharing. A clause giving you any refunds for pre-closing tax years, if they ever arrive.

Each has trade-offs covered in earn-outs in cannabis deals. Buyers accept these terms more readily than a higher fixed price, because they pay only if the benefit is real.

The cost of waiting

Waiting is not free. While you wait you carry another year of operating risk, licence renewals, price compression, staff turnover, and your own fatigue. If rescheduling arrives, many owners who were also waiting will list at the same time. And a sale takes months after you decide; see how long it takes to sell. Owners who want to sell into a post-rescheduling market need to be prepared before it, not start after it. The longer view is in cannabis exit planning.

This page is educational and is not legal, tax, or investment advice. Federal status changes quickly; confirm current facts before acting.